Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells and Antibodies in Drug Discovery Europe 2018

Stem Cells and Antibodies in Drug Discovery Europe 2018 Agenda

Enabling Early Stage Muscle Drug Discovery with MyoScreen™, a High-throughput High-content Phenotypic Screening Platform Deploying Micropatterned Human Primary Skeletal Myotubes

Joanne Young, Senior Scientist, Cytoo SA

CYTOO has recently developed a disease relevant phenotypic muscle drug discovery platform to fully leverage the characterization of compounds at an early stage of the drug discovery pipeline. MyoScreen™ deploys imaging and image-analysis methodology along with a micropatterned plate system that allows the precise control of myotube length and the formation of highly aligned myotubes.
In this seminar, I will discuss the robust performance of the MyoScreen™ platform and show how it exploits the improved architecture and maturity of micropatterned myotubes, which are superior to standard 2D culture, to quantitatively analyze drug effects on proliferation, hypertrophy/atrophy, acetylcholine receptors, as well as providing a screening index of contractile force. I will also describe actual use of MyoScreen™ in a primary screen with secondary hit validation, focusing on two intriguing hits that were identified to enhance myotube function by distinct mechanisms of action.